| Literature DB >> 17217042 |
Z Chen1, W L Zhao, Z X Shen, J M Li, S J Chen, J Zhu, V Lallemand-Breittenbach, J Zhou, M C Guillemin, D Vitoux, H de Thé.
Abstract
Arsenic has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. Indeed, arsenic trioxide combined with all-trans retinoic acid shows a synergistic effect. Mechanistically, arsenic targets the key leukemogenic protein PML-RARalpha, setting up a new example of molecular target-based cancer therapy.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17217042 DOI： 10.1007/978-3-540-34594-7_8
Source DB: PubMed Journal: Curr Top Microbiol Immunol ISSN： 0070-217X Impact factor: 4.291